Pseudopterosin A-D Modulates Dendritic Cell Activation in Skin Sensitization
Marine Drugs · 10.06.2025 · 23 (6) · 245
DOI: 10.3390/md23060245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, online erschienen am 10.06.2025. Verfasst von Johanna Maria Hölken und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine University Düsseldorf, Universitätsstraße 1, 40225 Düsseldorf, Germany. Hauptthemen laut MEDLINE: Dendritic Cells, Anti-Inflammatory Agents, Diterpenes, Dermatitis, Allergic Contact. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was funded by a grant to N.T. fromthe Bundesministerium für Ernährung und Landwirtschaft (BMEL), Bundesministerium für Ernährung und Landwirtschaft (BMEL).
Abstract (Originalsprache)
This study investigates the anti-inflammatory effects of the marine diterpene glycosides pseudopterosin A-D (PsA-D) in mitigating nickel sulfate (NiSO4)-induced skin sensitization. In dermal dendritic cell (DDC) surrogates, PsA-D pre-treatment significantly reduced NiSO4-induced upregulation of key activation surface markers, cluster of differentiation (CD)54 (~1.2-fold), and CD86 (~1.6-fold). Additionally, PsA-D inhibited the NiSO4-induced activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway by suppressing inhibitor of kappa B alpha (IκBα) degradation. Furthermore, PsA-D suppressed inflammatory responses by inhibiting the NiSO4-induced secretion of pro-inflammatory cytokines, including interleukin (IL)-8 (~6.8-fold), IL-6 (~2.2-fold), and IL-1β (~5.3-fold). In a full-thickness human skin model incorporating DDC surrogates, topical application of PsA-D effectively attenuated NiSO4-induced mRNA expression of IL-8 (~2.1-fold), IL-6 (~2.6-fold), and IL-1β (~2.2-fold), along with the key inflammatory mediators cyclooxygenase-2 (COX-2) (~3.5-fold) and NOD-like receptor family pyrin domain-containing 3 (NLRP3) (~2.1-fold). Overall, PsA-D demonstrated comparable efficacy to dexamethasone, a benchmark corticosteroid, providing a promising therapeutic alternative to corticosteroids for the treatment of skin sensitization and allergic contact dermatitis. However, to maximize PsA-D’s therapeutic potential, future studies on optimizing the bioavailability and formulation of PsA-D are required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine University Düsseldorf, Universitätsstraße 1, 40225 Düsseldorf, Germany.
- Department of Chemistry, Department of Biomedical Sciences, Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, PE C1A 4P3, Canada.
ORCID-Profile: Nicole Elisabeth Teusch
Förderung
- This research was funded by a grant to N.T. fromthe Bundesministerium für Ernährung und Landwirtschaft (BMEL)
- Bundesministerium für Ernährung und Landwirtschaft (BMEL)
Zitieren
APA
Hölken, J. M., Friedrich, K., Kerr, R., & Teusch, N. E. (2025). Pseudopterosin A-D Modulates Dendritic Cell Activation in Skin Sensitization. Marine Drugs, 23(6), 245. https://doi.org/10.3390/md23060245
Vancouver
Hölken JM, Friedrich K, Kerr R, Teusch NE. Pseudopterosin A-D Modulates Dendritic Cell Activation in Skin Sensitization. Marine Drugs. 2025;23(6):245. doi:10.3390/md23060245
BibTeX
@article{Hlken2025,
author = {Hölken, Johanna Maria and Friedrich, Katja and Kerr, Russel and Teusch, Nicole Elisabeth},
title = {Pseudopterosin A-D Modulates Dendritic Cell Activation in Skin Sensitization},
journal = {Marine Drugs},
year = {2025},
volume = {23},
number = {6},
pages = {245},
doi = {10.3390/md23060245}
}
EUVIMED